195 related articles for article (PubMed ID: 10369073)
21. The prescription pattern of Chinese herbal products that contain dang-qui and risk of endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan: a population-based study.
Wu CT; Lai JN; Tsai YT
PLoS One; 2014; 9(12):e113887. PubMed ID: 25485843
[TBL] [Abstract][Full Text] [Related]
22. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
23. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
24. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
25. Risk for endometrial cancer following breast cancer: a prospective study in Sweden.
Adami HO; Bergström R; Weiderpass E; Persson I; Barlow L; McLaughlin JK
Cancer Causes Control; 1997 Nov; 8(6):821-7. PubMed ID: 9427424
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen.
Kwan ML; Shi JM; Habel LA; Song J; Chung JW; Avila CC; Schottinger JE; Cheetham TC; Fletcher SW; Haque R
Breast Cancer Res Treat; 2016 Apr; 156(2):379-89. PubMed ID: 27002508
[TBL] [Abstract][Full Text] [Related]
28. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
29. Re: second cancers after adjuvant tamoxifen therapy for breast cancer.
Rutqvist LE
J Natl Cancer Inst; 1996 Oct; 88(20):1497-9; author reply, 1497-9. PubMed ID: 8841030
[No Abstract] [Full Text] [Related]
30. Risks of second malignancies after breast cancer treatment: Long-term results.
Bazire L; De Rycke Y; Asselain B; Fourquet A; Kirova YM
Cancer Radiother; 2017 Feb; 21(1):10-15. PubMed ID: 28034681
[TBL] [Abstract][Full Text] [Related]
31. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
Gao X; Fisher SG; Emami B
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1038-45. PubMed ID: 12829139
[TBL] [Abstract][Full Text] [Related]
32. Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer.
Ryu KJ; Kim MS; Lee JY; Nam S; Jeong HG; Kim T; Park H
JAMA Netw Open; 2022 Nov; 5(11):e2243951. PubMed ID: 36441547
[TBL] [Abstract][Full Text] [Related]
33. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
34. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
36. The risk of developing uterine sarcoma after tamoxifen use.
Lavie O; Barnett-Griness O; Narod SA; Rennert G
Int J Gynecol Cancer; 2008; 18(2):352-6. PubMed ID: 18334013
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
38. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mignotte H; Lasset C; Bonadona V; Lesur A; Luporsi E; Rodier JF; Cutuli B; Lasry S; Mauriac L; Granon C; Kerr C; Giard S; Hill C; de Lafontan B; de Gislain C; D'Anjou J; Fondrinier E; Lefeuvre C; Parache RM; Chauvin F
Int J Cancer; 1998 May; 76(3):325-30. PubMed ID: 9579567
[TBL] [Abstract][Full Text] [Related]
39. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients.
Robinson DC; Bloss JD; Schiano MA
Gynecol Oncol; 1995 Nov; 59(2):186-90. PubMed ID: 7590470
[TBL] [Abstract][Full Text] [Related]
40. Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.
Rubagotti A; Perrotta A; Casella C; Boccardo F
Ann Oncol; 1996 Mar; 7(3):239-44. PubMed ID: 8740786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
